These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23446700)

  • 1. A method for measurement of drug sensitivity of myeloma cells co-cultured with bone marrow stromal cells.
    Misund K; Baranowska KA; Holien T; Rampa C; Klein DC; Børset M; Waage A; Sundan A
    J Biomol Screen; 2013 Jul; 18(6):637-46. PubMed ID: 23446700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.
    Ramasamy K; Khatun H; Macpherson L; Caley MP; Sturge J; Mufti GJ; Schey SA; Calle Y
    Br J Haematol; 2012 Jun; 157(5):564-79. PubMed ID: 22428569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate.
    Holien T; Olsen OE; Misund K; Hella H; Waage A; Rø TB; Sundan A
    Eur J Haematol; 2013 Oct; 91(4):339-46. PubMed ID: 23869695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecule enhancers of rapamycin induce apoptosis in myeloma cells via GSK3A/B preferentially within a protective bone marrow microenvironment.
    Nekova TS; Dotterweich J; Schütze N; Einsele H; Stuhler G
    Br J Haematol; 2014 Oct; 167(2):272-4. PubMed ID: 24916065
    [No Abstract]   [Full Text] [Related]  

  • 5. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
    Nefedova Y; Landowski TH; Dalton WS
    Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
    Giuliani N; Colla S; Morandi F; Rizzoli V
    Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
    Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
    Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
    Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
    Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
    Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone.
    Grigorieva I; Thomas X; Epstein J
    Exp Hematol; 1998 Jul; 26(7):597-603. PubMed ID: 9657134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.
    Bam R; Khan S; Ling W; Randal SS; Li X; Barlogie B; Edmondson R; Yaccoby S
    BMC Cancer; 2015 Nov; 15():864. PubMed ID: 26545722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
    Bolzoni M; Storti P; Bonomini S; Todoerti K; Guasco D; Toscani D; Agnelli L; Neri A; Rizzoli V; Giuliani N
    Exp Hematol; 2013 Apr; 41(4):387-97.e1. PubMed ID: 23178378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translation of a tumor microenvironment mimicking 3D tumor growth co-culture assay platform to high-content screening.
    Krausz E; de Hoogt R; Gustin E; Cornelissen F; Grand-Perret T; Janssen L; Vloemans N; Wuyts D; Frans S; Axel A; Peeters PJ; Hall B; Cik M
    J Biomol Screen; 2013 Jan; 18(1):54-66. PubMed ID: 22923784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel-releasing mesenchymal stromal cells inhibit the growth of multiple myeloma cells in a dynamic 3D culture system.
    Bonomi A; Steimberg N; Benetti A; Berenzi A; Alessandri G; Pascucci L; Boniotti J; Coccè V; Sordi V; Pessina A; Mazzoleni G
    Hematol Oncol; 2017 Dec; 35(4):693-702. PubMed ID: 27283119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo.
    Xu S; Menu E; De Becker A; Van Camp B; Vanderkerken K; Van Riet I
    Stem Cells; 2012 Feb; 30(2):266-79. PubMed ID: 22102554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
    Shipman CM; Croucher PI
    Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
    Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
    Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy.
    Slone WL; Moses BS; Hare I; Evans R; Piktel D; Gibson LF
    Oncotarget; 2016 Apr; 7(17):23439-53. PubMed ID: 27015556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma.
    Stewart HJ; Kishikova L; Powell FL; Wheatley SP; Chevassut TJ
    Exp Hematol; 2011 Mar; 39(3):330-8. PubMed ID: 21184800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells.
    Silva A; Jacobson T; Meads M; Distler A; Shain K
    J Vis Exp; 2015 Jul; (101):e53070. PubMed ID: 26274375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.